Key points are not available for this paper at this time.
These preliminary results suggest that TMA using OBT fusion is precise and safe in patients with intermediate risk localised prostate cancer. Further inclusions and follow-up are needed to assess oncological outcome.
Delongchamps et al. (2024) studied this question.